Dr Eva Ciruelos examines why new treatments are required to address unmet needs in patients with HER2-positive advanced breast cancer and describes how novel therapies act to target resistance to anti-HER2 therapies.1/3 Next Interview
Prof. Rupert Bartsch reviews the latest efficacy and safety data for later-line novel HER2-targeted therapies in patients with HER2-positive advanced breast cancer.2/3 Next Interview
Prof. Sibylle Loibl discusses how novel treatment options may influence the future clinical management of patients with HER2-positive advanced breast cancer.3/3 Take CME Test
Overview & Learning Objectives
In this activity, experts in HER2-positive breast cancer discuss the rationale and evidence for recently approved and emerging novel therapies and their potential impact in the management of patients with HER2-positive advanced breast cancer.
This activity has been jointly provided by Oakstone and touchIME ONCOLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians. read more
This activity has been designed to meet the educational needs of oncologists involved in the management of patients with breast cancer.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Dr Eva Ciruelos discloses: Consultant/advisory board fees and congress assistance from Eli Lilly, Novartis, Pfizer and Roche.
Prof. Rupert Bartsch discloses: Grant/research support from Daiichi Sankyo, Novartis and Roche; Honoraria from Accord Healthcare, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Novartis, Pfizer, Roche and Sandoz; Advisory Board fees from AstraZeneca, Celgene; Daiichi Sankyo, Eisai, Eli Lilly, MSD, Novartis, Roche and Samsung.
Prof. Sibylle Loibl discloses: Grant/research support from Abbvie, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Immunomedics, Novartis, Pfizer and Roche; Consultant/advisory board fees from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Daiichi Sankyo, Eli Lilly, Immunomedics, Merck, MSD, Novartis, Pierre Fabre, Pfizer, Puma Biotechnology, Roche, Seagen and Samsung; Speaker bureau fees from AbbVie, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eli Lilly, Novartis, Pfizer, Roche, Seagen and Samsung; Other Chugai Pharmaceutical Co.
Walter Murray Yarbrough, MD, FACP, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™️. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Date of original release: 14 December. Date credits expire: 14 December.
After watching this activity, you should be able to:
- Outline the rationale for novel treatment options for HER2-positive advanced breast cancer
- Recall the clinical data for emerging later-line treatment options for patients with HER2-positive advanced breast cancer
- Describe how novel treatment options may impact future management and address unmet needs in patients with HER2-positive breast cancer